Other type I correctors, such as C18 (VRT-534; from the Cystic Fibrosis Foundation’s CFTR Compound Program), ABBV-2222 (formerly GLPG-2222; also known as galicaftor), FDL-169 and trimethylangelicin (derivatives) rescue CFTR through a similar MoA [123,138,154,155]. This evidence concerns the gene CFTR and cystic fibrosis.